Regeneron Pharmaceuticals, Inc. $REGN Stock: First Trust Advisors LP Boosts Position

First Trust Advisors LP lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 51.1% in the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 826,770 shares of the biopharmaceutical company’s stock after acquiring an additional 279,638 shares during the period. First Trust Advisors LP owned 0.80% of Regeneron Pharmaceuticals worth $626,915,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in REGN. BlackRock Inc. purchased a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $5,682,636,000. Legal & General Group Plc purchased a new stake in Regeneron Pharmaceuticals in the second quarter worth $473,872,000. Bank of New York Mellon Corp purchased a new stake in Regeneron Pharmaceuticals in the second quarter worth $472,950,000. Aberdeen Group plc grew its stake in Regeneron Pharmaceuticals by 560.7% in the third quarter. Aberdeen Group plc now owns 671,042 shares of the biopharmaceutical company’s stock worth $508,831,000 after purchasing an additional 569,476 shares during the period. Finally, Deutsche Bank AG bought a new position in Regeneron Pharmaceuticals in the second quarter worth $323,249,000. Institutional investors own 83.31% of the company’s stock.

Key Stories Impacting Regeneron Pharmaceuticals

Investors following REGN have been watching these stories:

  • Positive Sentiment: Regeneron plans to present new hematology data at the December ASH meeting, including potentially pivotal Ordspono results in marginal zone lymphoma. The data could provide further evidence of the company’s pipeline opportunity, though it is not yet a clinical or regulatory outcome. Regeneron ASH data announcement
  • Neutral Sentiment: Director Andrew Murphy sold 5,011 shares under a pre-arranged Rule 10b5-1 plan. He retained 46,779 shares afterward, making the transaction a limited signal about his view of the company. Insider transaction report
  • Neutral Sentiment: Livsayis will compete with established treatments for generalized myasthenia gravis, so adoption and commercial performance remain important to watch despite its distinctive dosing schedule. Livsayis competitive context

Insider Activity

In other news, EVP Marion Mccourt sold 1,215 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total value of $1,032,750.00. Following the completion of the transaction, the executive vice president owned 13,134 shares of the company’s stock, valued at $11,163,900. The trade was a 8.47% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christine Poon sold 7,830 shares of the company’s stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $969.09, for a total transaction of $7,587,974.70. Following the completion of the transaction, the director owned 5,219 shares in the company, valued at approximately $5,057,680.71. The trade was a 60.00% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 32,039 shares of company stock valued at $29,825,285. 6.97% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Stock Down 0.3%

REGN stock opened at $920.69 on Friday. Regeneron Pharmaceuticals, Inc. has a twelve month low of $591.52 and a twelve month high of $991.73. The company has a quick ratio of 2.89, a current ratio of 3.35 and a debt-to-equity ratio of 0.06. The firm has a market cap of $95.25 billion, a PE ratio of 20.33, a price-to-earnings-growth ratio of 1.22 and a beta of 0.10. The business has a 50 day moving average of $829.76 and a 200 day moving average of $752.07.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last released its earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 EPS for the quarter, topping the consensus estimate of $16.51 by $3.56. Regeneron Pharmaceuticals had a return on equity of 16.01% and a net margin of 28.51%. The business had revenue of $5.12 billion for the quarter, compared to the consensus estimate of $4.58 billion. During the same period in the previous year, the company posted $11.83 earnings per share. The company’s revenue for the quarter was up 36.3% compared to the same quarter last year. On average, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 58.26 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 3rd. Stockholders of record on Friday, November 20th will be issued a dividend of $0.94 per share. The ex-dividend date is Friday, November 20th. This represents a $3.76 annualized dividend and a dividend yield of 0.4%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 8.30%.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on REGN. JPMorgan Chase & Co. increased their price objective on Regeneron Pharmaceuticals from $950.00 to $1,050.00 and gave the stock an “overweight” rating in a report on Friday, October 30th. Sanford C. Bernstein boosted their target price on shares of Regeneron Pharmaceuticals from $756.00 to $812.00 and gave the company a “market perform” rating in a report on Monday, November 2nd. Wall Street Zen raised shares of Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Sunday, September 20th. UBS Group raised shares of Regeneron Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their target price for the stock from $660.00 to $978.00 in a research report on Thursday, October 15th. Finally, Evercore increased their price target on shares of Regeneron Pharmaceuticals from $825.00 to $850.00 and gave the stock an “outperform” rating in a research note on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $904.41.

Get Our Latest Report on Regeneron Pharmaceuticals

About Regeneron Pharmaceuticals

(Free Report)

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions. The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.

Read More

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.